Ivosidenib as Post-HSCT Maintenance for AML

Clinical trial NCT06707493 · RECRUITING

Trial details

NCT number: NCT06707493
Sponsor: Massachusetts General Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IDH1 Mutation Acute Myeloid Leukemia (AML)Hematopoietic Stem Cell Transplant (HSCT)

Start date: 2026-01-16
Primary completion: 2028-01-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.